Gottfried Doelken

862 total citations
15 papers, 296 citations indexed

About

Gottfried Doelken is a scholar working on Pathology and Forensic Medicine, Oncology and Hematology. According to data from OpenAlex, Gottfried Doelken has authored 15 papers receiving a total of 296 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pathology and Forensic Medicine, 7 papers in Oncology and 6 papers in Hematology. Recurrent topics in Gottfried Doelken's work include Lymphoma Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Acute Myeloid Leukemia Research (4 papers). Gottfried Doelken is often cited by papers focused on Lymphoma Diagnosis and Treatment (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Acute Myeloid Leukemia Research (4 papers). Gottfried Doelken collaborates with scholars based in Germany, Switzerland and Australia. Gottfried Doelken's co-authors include Gerhard Ehninger, Peter Borchmann, Lorenz Truemper, Mathias Haenel, Andreas Viardot, Norbert Schmitz, Marita Ziepert, Markus Loeffler, Thomas Kiefer and Axel Krämer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and The Lancet Oncology.

In The Last Decade

Gottfried Doelken

13 papers receiving 292 citations

Peers

Gottfried Doelken

PFM

ONCOL

NEURO

GENET

PRM

Karolyn Morris United States

Dubravka Sertić Croatia

Yasunobu Sekiguchi Japan

Christoph Busemann Germany

H. G. Derigs Germany

Teresio Motta Italy

Musa Alzahrani Saudi Arabia

Pamela Vezzoli Italy

Francesco Volzone Italy

Stephen D. Anesi United States

Karolyn Morris United States

Gottfried Doelken

190 ×1.1

PFM

120 ×0.7

ONCOL

99 ×1.3

NEURO

83 ×1.2

GENET

32 ×0.6

PRM

Citations per year, relative to Gottfried Doelken Gottfried Doelken (= 1×) peers Karolyn Morris

Countries citing papers authored by Gottfried Doelken

Since Specialization

Citations

This map shows the geographic impact of Gottfried Doelken's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Gottfried Doelken with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Gottfried Doelken more than expected).

Fields of papers citing papers by Gottfried Doelken

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Gottfried Doelken. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Gottfried Doelken. The network helps show where Gottfried Doelken may publish in the future.

Co-authorship network of co-authors of Gottfried Doelken

This figure shows the co-authorship network connecting the top 25 collaborators of Gottfried Doelken. A scholar is included among the top collaborators of Gottfried Doelken based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Gottfried Doelken. Gottfried Doelken is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Schmitz, Norbert, Maike Nickelsen, Marita Ziepert, et al.. (2012). Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002-1). The Lancet Oncology. 13(12). 1250–1259. 152 indexed citations

Assouline, Sarit, Valéria Buccheri, Alain Delmer, et al.. (2012). Subcutaneous Rituximab in Combination with Fludarabine and Cyclophosphamide for Patients with CLL: Initial Results of a Phase Ib Study (SAWYER [BO25341]) Show Non-Inferior Pharmacokinetics and Comparable Safety to That of Intravenous Rituximab. Blood. 120(21). 1637–1637. 5 indexed citations

Schmitz, Norbert, Maike Nickelsen, Marita Ziepert, et al.. (2011). Conventional chemoimmunotherapy (R-CHOEP-14) or high-dose therapy (R-Mega-CHOEP) for young, high-risk patients with aggressive B-cell lymphoma: Final results of the randomized Mega-CHOEP trial of the German High-Grade Non-Hodgkin Lymphona Study Group (DSHNHL).. Journal of Clinical Oncology. 29(15_suppl). 8002–8002. 17 indexed citations

Niederwieser, Dietger, Leo F. Verdonck, Jan J. Cornelissen, et al.. (2011). Long Term Outcome After Low Dose TBI Based Conditioning Hematopoietic Stem Cell Transplantation (HSCT) From Related and Unrelated Donors for Older Patients with AML. Blood. 118(21). 2030–2030. 1 indexed citations

Stürmer, Martin, Katrin Zimmermann, Carlos Fritzsche, et al.. (2010). Regional spread of HIV-1 M subtype B in middle-aged patients by random env-C2V4 region sequencing. Medical Microbiology and Immunology. 199(2). 123–128. 6 indexed citations

Niederwieser, D., Ute Hegenbart, Georg Maschmeyer, et al.. (2010). Improvement of leukemia-free survival (LFS) and reduction of relapse incidence by allogeneic stem cell transplantation (SCT) in elderly patients (pts) with AML irrespective of the FLT3-ITD and npm status except npm+/flt3(ITD)-.. Journal of Clinical Oncology. 28(15_suppl). 6505–6505. 2 indexed citations

Wandt, Hannes, Kerstin Schaefer‐Eckart, M. Thalheimer, et al.. (2009). Experience with a Therapeutic Platelet Transfusion Strategy in Acute Myeloid Leukemia: Preliminary Results of a Randomized Multicenter Study After Enrolment of 175 Patients.. Blood. 114(22). 20–20. 9 indexed citations

Herold, Michael, Antje Haas, Sabine Neser, et al.. (2007). Immunochemotherapy (R-MCP) Is Not Superior to Chemotherapy (MCP) Alone in Advanced Mantle Cell Lymphoma - 42 Months Follow Up Results of the OSHO 39 Study.. Blood. 110(11). 4474–4474.

Herold, Michael, Antje Haas, Sabine Neser, et al.. (2006). Addition of Rituximab to First-Line MCP (Mitoxantrone, Chlorambucil, Prednisolone) Chemotherapy Prolongs Survival in Advanced Follicular Lymphoma - 4 Year Follow-Up Results of a Phase III Trial of the East German Study Group Hematology and Oncology (OSHO#39).. Blood. 108(11). 484–484. 10 indexed citations

10.

Doelken, Gottfried, et al.. (2005). POOR OUTCOME OF TWO CHILDREN WITH RELAPSED STATE STAGE IV ALVEOLAR RHABDOMYOSARCOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION. Pediatric Hematology and Oncology. 22(8). 699–703. 5 indexed citations

11.

Casper, J., Wolfgang Knauf, IW Blau, et al.. (2004). Treosulfan/fludarabine: a new conditioning regimen in allogeneic transplantation.. PubMed. 83 Suppl 1. S70–1. 19 indexed citations

12.

Kiefer, Thomas, et al.. (2003). Do cancer patients with chemotherapy-induced leukopenia benefit from an antiseptic chlorhexidine-based oral rinse? A double-blind, block-randomized, controlled study. Journal of Hospital Infection. 53(4). 283–291. 49 indexed citations

13.

Sucker, Christoph, et al.. (2002). Unusual Sites of Involvement in Non-Hodgkin's Lymphoma. Journal of Clinical Oncology. 20(21). 4397–4398. 8 indexed citations

14.

Snyder, David S., David O. Findley, Stephen J. Forman, et al.. (1988). Fractionated total body irradiation and high dose cyclophosphamide: a preparative regimen for bone marrow transplantation for patients with hematologic malignancies in first complete remission. Annals of Hematology. 57(1). 7–13. 11 indexed citations

15.

Doelken, Gottfried & Gregory Klein. (1977). Solid-phase radioimmunoassay for Epstein-Barr virus-associated membrane antigen prepared from B95-8 cell culture supernatants. [/sup 125/I tracer technique]. OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information). 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact